Cargando…

Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia

BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. It requires a long and rigorous course of chemotherapy treatments. 6-Mercaptopurine (6-MP) is one of the primary drugs used in chemotherapy. Unfortunately, its efficacy has been limited due to its i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yaru, Mei, Dong, Yuan, Jinjie, Han, Jiaqi, Xu, Jiamin, Sun, Ning, He, Huan, Yang, Changqing, Zhao, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886780/
https://www.ncbi.nlm.nih.gov/pubmed/33603372
http://dx.doi.org/10.2147/IJN.S290466
_version_ 1783651869563813888
author Zou, Yaru
Mei, Dong
Yuan, Jinjie
Han, Jiaqi
Xu, Jiamin
Sun, Ning
He, Huan
Yang, Changqing
Zhao, Libo
author_facet Zou, Yaru
Mei, Dong
Yuan, Jinjie
Han, Jiaqi
Xu, Jiamin
Sun, Ning
He, Huan
Yang, Changqing
Zhao, Libo
author_sort Zou, Yaru
collection PubMed
description BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. It requires a long and rigorous course of chemotherapy treatments. 6-Mercaptopurine (6-MP) is one of the primary drugs used in chemotherapy. Unfortunately, its efficacy has been limited due to its insolubility, poor bioavailability and serious adverse effects. To overcome these drawbacks, we constructed 6-mercaptopurine (6-MP)-loaded nanomedicines (6-MPNs) with biodegradable poly(lactide-co-glycolide) (PLGA) to enhance the anticancer efficacy of 6-MP. METHODS: We prepared the 6-MPNs using a double-emulsion solvent evaporation method, characterizing them for the physicochemical properties. We then investigated the plasma, intestinal region and other organs in Sprague Dawley (SD) rats for pharmacokinetics. Additionally, we evaluated its anticancer efficacy in vitro on the human T leukemia cell line Jurkat and in vivo on the ALL model mice. RESULTS: The 6-MPNs were spherical in shape with uniform particle size and high encapsulation efficiency. The in vitro release profile showed that 6-MPNs exhibited a burst release that a sustained release phase then followed. The apoptosis assay demonstrated that 6-MPNs could improve the in vitro cytotoxicity in Jurkat cells. Pharmacokinetics profiles revealed that 6-MPNs had improved oral bioavailability. Tissue distribution experiments indicated that 6-MPNs increased the duodenum absorption of 6-MP, at the same time having a low accumulation of the toxic metabolites of 6-MP. The in vivo pharmacodynamics study revealed that 6-MPNs could prolong the survival time of the ALL model mice. The prepared 6-MPNs, therefore, have superior properties in terms of anticancer efficacy against ALL with reduced systemic toxicity. CONCLUSION: Our nanomedicines provide a promising delivery strategy for 6-MP; they offer a simple preparation method and high significance for clinical translation.
format Online
Article
Text
id pubmed-7886780
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78867802021-02-17 Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia Zou, Yaru Mei, Dong Yuan, Jinjie Han, Jiaqi Xu, Jiamin Sun, Ning He, Huan Yang, Changqing Zhao, Libo Int J Nanomedicine Original Research BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. It requires a long and rigorous course of chemotherapy treatments. 6-Mercaptopurine (6-MP) is one of the primary drugs used in chemotherapy. Unfortunately, its efficacy has been limited due to its insolubility, poor bioavailability and serious adverse effects. To overcome these drawbacks, we constructed 6-mercaptopurine (6-MP)-loaded nanomedicines (6-MPNs) with biodegradable poly(lactide-co-glycolide) (PLGA) to enhance the anticancer efficacy of 6-MP. METHODS: We prepared the 6-MPNs using a double-emulsion solvent evaporation method, characterizing them for the physicochemical properties. We then investigated the plasma, intestinal region and other organs in Sprague Dawley (SD) rats for pharmacokinetics. Additionally, we evaluated its anticancer efficacy in vitro on the human T leukemia cell line Jurkat and in vivo on the ALL model mice. RESULTS: The 6-MPNs were spherical in shape with uniform particle size and high encapsulation efficiency. The in vitro release profile showed that 6-MPNs exhibited a burst release that a sustained release phase then followed. The apoptosis assay demonstrated that 6-MPNs could improve the in vitro cytotoxicity in Jurkat cells. Pharmacokinetics profiles revealed that 6-MPNs had improved oral bioavailability. Tissue distribution experiments indicated that 6-MPNs increased the duodenum absorption of 6-MP, at the same time having a low accumulation of the toxic metabolites of 6-MP. The in vivo pharmacodynamics study revealed that 6-MPNs could prolong the survival time of the ALL model mice. The prepared 6-MPNs, therefore, have superior properties in terms of anticancer efficacy against ALL with reduced systemic toxicity. CONCLUSION: Our nanomedicines provide a promising delivery strategy for 6-MP; they offer a simple preparation method and high significance for clinical translation. Dove 2021-02-12 /pmc/articles/PMC7886780/ /pubmed/33603372 http://dx.doi.org/10.2147/IJN.S290466 Text en © 2021 Zou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zou, Yaru
Mei, Dong
Yuan, Jinjie
Han, Jiaqi
Xu, Jiamin
Sun, Ning
He, Huan
Yang, Changqing
Zhao, Libo
Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
title Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
title_full Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
title_fullStr Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
title_full_unstemmed Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
title_short Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
title_sort preparation, characterization, pharmacokinetic, and therapeutic potential of novel 6-mercaptopurine-loaded oral nanomedicines for acute lymphoblastic leukemia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886780/
https://www.ncbi.nlm.nih.gov/pubmed/33603372
http://dx.doi.org/10.2147/IJN.S290466
work_keys_str_mv AT zouyaru preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT meidong preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT yuanjinjie preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT hanjiaqi preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT xujiamin preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT sunning preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT hehuan preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT yangchangqing preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia
AT zhaolibo preparationcharacterizationpharmacokineticandtherapeuticpotentialofnovel6mercaptopurineloadedoralnanomedicinesforacutelymphoblasticleukemia